Clinical trials: Hepatic Arterial Infusion Chemotherapy
Thrombocytopenia, Hepatocellular Carcinoma
Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC
This study is conducted to evaluate the efficacy of avatrombopag for thrombocytopenia in patients with hepatocellular carcinoma (HCC) who intend to undergo transarterial chemoembolization (TACE) and/or hepatic arterial infusion…
- Trial name
- NCT06001567
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma (HCC)
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Study Design: This is a pilot study with a single arm in a single centre assessing safety and efficacy of durvalumab in combination with bevacizumab and HAIC followed by SBRT.
- Trial name
- NCT07012798
- Testing
- Durvalumab, Bevacizumab, HAIC of FOLFOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE.
- Trial name
- NCT05121571
- Testing
- HAIC, Sorafenib
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Liver Neoplasms
HAI Via Interventionally Implanted Port Catheter Systems
Procedures to provide interventional implantation of a port catheter system into the hepatic artery and adjacent regional chemotherapy of the liver are optimized in the scope of an open, single-arm trial in patients with…
- Conditions
- Colorectal Cancer, Liver Neoplasms, Hepatocellular Carcinoma, Gallbladder Cancer
- Trial name
- NCT00356161
- Testing
- interventionally implanted hepatic arterial port catheter
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Charite University, Berlin, Germany
Hepatecellular Carcinoma, Liver Injury
HAIC vs. TACE Combined With ICIs and TKIs in Intermediate-to-Advanced HCC: A Multicenter Study on Liver Injury and Survival
The purpose of this study is to compare the liver injury induced by HAIC combined with PD-1/PD-L1 inhibitors and TKIs versus triple therapy with TACE in the treatment of patients with advanced HCC; to compare the efficacy of the…
- Conditions
- Hepatecellular Carcinoma, Liver Injury, HAIC(Hepatic Artery Infusion Chemotherapy), TACE(Transcatheter Arterial Chemoembolization)
- Trial name
- NCT07277192
- Where
- China
- Volunteers
- 562 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Intrahepatic Cholangiocarcinoma
HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma
Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%.
- Trial name
- NCT05400902
- Testing
- HAIC Combined with Tislelizumab and Apatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Binkui Li
Hepatocellular Carcinoma (HCC), Emotional Distress
Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
This study is a multicenter, prospective, observational clinical trial designed to evaluate the impact of baseline emotional status on the clinical outcomes of patients with BCLC stage B/C hepatocellular carcinoma undergoing HAIC…
- Conditions
- Hepatocellular Carcinoma (HCC), Emotional Distress, HAIC(Hepatic Artery Infusion Chemotherapy), Immunotherapy
- Trial name
- NCT07436845
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Colorectal Cancer, Liver Neoplasms
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of the study to determine and evaluate the safety and tolerability of repeated treatments with a genetically engineered herpes simplex virus…
- Trial name
- NCT00149396
- Testing
- NV1020
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- MediGene
Colorectal Cancer, Metastatic Cancer
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Hepatic arterial infusion uses a catheter to carry tumor-killing substances directly into the liver. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT00492999
- Testing
- dexamethasone, floxuridine, fluorouracil
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
This is a prospective, single-armed, multicentric, explorative phase II clinical research of conversional therapy with combination of hepatic arterial infusion chemotherapy(HAIC), Donafenib Tosilate and Toripalimab for…
- Trial name
- NCT05493332
- Testing
- HAIC(FOLFOX), Oxaliplatin, Leucovorin
- Volunteers
- 93 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
C-staged Hepatocellular Carcinoma in BCLC Classification
A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification
This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Apatinib and Camrelizumab (treatment group) versus Apatinib and Camrelizumab (control group) for C-staged…
- Trial name
- TRIPLET-III (NCT05313282)
- Testing
- Hepatic Arterial Infusion combined with Apatinib and Camrelizumab, Apatinib combined with Camrelizumab
- Where
- 5 sites in China
- Volunteers
- 140 people
- Sponsor
- Sun Yat-sen University
Intraocular Melanoma, Metastatic Cancer
Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
RATIONALE: Drugs used in chemotherapy, such as fotemustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00110123
- Testing
- fotemustine, isolated perfusion
- Where
- 8 sites in Italy, Poland and 2 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hepatocellular Carcinoma
Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
Liver cancer is a highly lethal malignancy and has become increasingly important in western countries. The management of liver cancer is complex.
- Trial name
- ALICE (NCT06904170)
- Testing
- Durvalumab Plus Tremelimumab, HAIC (GEMOX)
- Where
- 11 sites in France
- Volunteers
- 196 people
- Sponsor
- UNICANCER
HepatoCellular Carcinoma
Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil
The purpose of this phase II study is to determine the recommended dose, as well as the safety and efficacy of the combination of oxaliplatin, leucovorin and 5-Fu introduced by hepatic arterial infusion chemotherapy (HAIC) in…
- Trial name
- NCT02987699
- Testing
- 5-Fu, oxaliplatin , leucovorin
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer Metastatic
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
This prospective, randomized, controlled clinical study aims to evaluate the objective remission rate of FOLFOX hepatic artery infusion chemotherapy (HAI) in combination with systemic irinotecan with or without bevacizumab versus…
- Trial name
- NCT05727163
- Testing
- Dexamethasone, Anisodamine, Oxaliplatin
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Sun Yat-sen University
Radial Artery Occlusion
Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy
The present investigation is designed as a single-blind, randomized, controlled, bicentric trial. The objective is to ascertain whether the subcutaneous administration of enoxaparin sodium for prophylactic anticoagulation during…
- Trial name
- NCT06293287
- Testing
- Subcutaneous enoxaparin sodium
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
Colorectal Cancer, Metastatic Cancer
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
The purpose of this study is to find the highest dose that can be given safely to people who have had liver disease resected. This is a Phase I study.
- Trial name
- NCT00059930
- Testing
- FOLFOX regimen, dexamethasone, floxuridine
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma (HCC)
The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study
This is a multicenter，retrospective study to explore the effectiveness and safety of Atezo/Bev plus hepatic artery infusion chemotherapy (HAIC) among adult patients with high-risk HCC in real-world clinical practice in China.
- Trial name
- NCT07272265
- Testing
- Atezolizumab & Bevacizumab, FOLFOX-HAIC
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and toripalimab in patients with advanced hepatocellular…
- Trial name
- NCT04044313
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shi Ming
HCC - Hepatocellular Carcinoma
HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure
For patients with advanced liver cancer who have progressed after first-line targeted and immunotherapy , there is currently no standard treatment regimen for second-line therapy.
- Trial name
- NCT06375317
- Testing
- PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets
- Volunteers
- 42 people
- Sponsor
- Yehua Shen